HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma

The expression of human leukocyte antigen-G (HLA-G) and HLA class II protein was studied by immunohistochemical staining of lymph nodes from 148 patients with diffuse large B-cell lymphoma (DLBCL) and related to the clinical course of the disease. Negative HLA-G expression was associated with a lowe...

Full description

Saved in:
Bibliographic Details
Published in:Archivum Immunologiae et Therapiae Experimentalis 2016-06, Vol.64 (3), p.225-240
Main Authors: Jesionek-Kupnicka, Dorota, Bojo, Marcin, Prochorec-Sobieszek, Monika, Szumera-Ciećkiewicz, Anna, Jabłońska, Joanna, Kalinka-Warzocha, Ewa, Kordek, Radzisław, Młynarski, Wojciech, Robak, Tadeusz, Warzocha, Krzysztof, Lech-Maranda, Ewa
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biomedical and Life Sciences
Biomedicine
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Histocompatibility Antigens Class II - immunology
Histocompatibility Antigens Class II - metabolism
HLA-G Antigens - immunology
HLA-G Antigens - metabolism
Humans
Immunohistochemistry
Immunology
Immunotherapy - methods
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - metabolism
Lymphoma, Large B-Cell, Diffuse - mortality
Male
Middle Aged
Original Article
Pharmacology/Toxicology
Prednisone - administration & dosage
Probability
Prognosis
Regression Analysis
Remission Induction
Treatment Outcome
Vincristine - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The expression of human leukocyte antigen-G (HLA-G) and HLA class II protein was studied by immunohistochemical staining of lymph nodes from 148 patients with diffuse large B-cell lymphoma (DLBCL) and related to the clinical course of the disease. Negative HLA-G expression was associated with a lower probability of achieving a complete remission ( p  = 0.04). Patients with negative HLA-G expression tended towards a lower 3-year overall survival (OS) rate compared to those with positive expression of HLA-G ( p  = 0.08). When restricting the analysis to patients receiving chemotherapy with rituximab, the estimated 3-year OS rate of patients with positive HLA-G expression was 73.3 % compared with 47.5 % ( p  = 0.03) in those with negative expression. Patients with negative HLA class II expression presented a lower 3-year OS rate compared to subjects with positive expression ( p  = 0.04). The loss of HLA class II expression ( p  = 0.05) and belonging to the intermediate high/high IPI risk group ( p  = 0.001) independently increased the risk of death. HLA class II expression also retained its prognostic value in patients receiving rituximab; the 3-year OS rate was 65.3 % in patients with positive HLA class II expression versus 29.6 % ( p  = 0.04) in subjects that had loss of HLA class II expression. To our knowledge, for the first time, the expression of HLA-G protein in DLBCL and its association with the clinical course of the disease was demonstrated. Moreover, the link between losing HLA class II protein expression and poor survival of patients treated with immunochemotherapy was confirmed.
ISSN:0004-069X
1661-4917
DOI:10.1007/s00005-015-0372-8